%	O
%	O
TITLE	O

Increasing	O
rates	O
of	O
low	O
-	O
risk	O
human	O
papillomavirus	O
infections	O
in	O
patients	O
with	O
oral	O
cavity	O
squamous	O
cell	O
carcinoma	O
:	O
association	O
with	O
clinical	O
outcomes	O
.	O

%	O
%	O
ABSTRACT	O

Although	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
infections	O
have	O
been	O
causally	O
linked	O
to	O
oral	O
cavity	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
,	O
the	O
potential	O
role	O
of	O
low	O
-	O
risk	O
HPV	O
(	O
LR	O
-	O
HPV	O
)	O
types	O
in	O
the	O
pathogenesis	O
of	O
this	O
malignancy	O
remains	O
unclear	O
.	O
We	O
sought	O
to	O
investigate	O
the	O
distribution	O
of	O
HPV	O
genotypes	O
and	O
their	O
prognostic	O
significance	O
in	O
OSCC	O
patients	O
treated	O
by	O
radical	O
surgery	O
,	O
either	O
with	O
or	O
without	O
adjuvant	O
therapy	O
.	O
We	O
studied	O
two	O
non	O
-	O
overlapping	O
OSCC	O
cohorts	O
for	O
the	O
periods	O
2005	B-Study_Time
-	I-Study_Time
2006	I-Study_Time
(	O
2005	B-Study_Cohort
cohort	I-Study_Cohort
,	I-Study_Cohort
n	I-Study_Cohort
=	I-Study_Cohort
204	I-Study_Cohort
)	O
and	O
2010	B-Study_Time
-	I-Study_Time
2011	I-Study_Time

(	O
2010	B-Study_Cohort
cohort	I-Study_Cohort
,	I-Study_Cohort
n	I-Study_Cohort
=	I-Study_Cohort
206	I-Study_Cohort
)	O
.	O

Paraffin	O
-	O
embedded	O
tissue	B-HPV_Sample_Type
blocks	O
were	O
collected	O
,	O
and	O
the	O
HPV	O
genotype	O
was	O
determined	O
using	O
PCR	B-HPV_Lab_Technique
plus	O
HPV	O
blot	O
tests	O
.	O

The	O
primary	O
study	O
endpoint	O
was	O
the	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV	O
genotypes	O
.	O

The	O
secondary	O
endpoints	O
were	O
the	O
2	O
-	O
year	O
therapeutic	O
outcomes	O
.	O
The	O
overall	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV	O
infections	O
did	O
not	O
differ	O
significantly	O
in	O
the	O
two	O
study	O
cohorts	O
.	O

However	O
,	O
the	O
prevalence	B-Incidence_or_Prevalence
of	O
LR	O
-	O
HPV	O
was	O
significantly	O
higher	O
in	O
the	O
2010	O
cohort	O
than	O
in	O
the	O
2005	O
cohort	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

The	O
overall	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV	O
infections	O
was	O
not	O
significantly	O
associated	O
with	O
the	O
2	O
-	O
year	O
outcomes	O
.	O

However	O
,	O
multivariate	O
analysis	O
demonstrated	O
that	O
LR	O
-	O
HPV	O
infection	O
was	O
a	O
predictor	O
of	O
poor	O
2	O
-	O
year	O
disease	O
-	O
free	O
survival	O
(	O
p	O
=	O
0	O
.	O
036	O
,	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
3	O
.	O
1	O
)	O
,	O
disease	O
-	O
specific	O
survival	O
(	O
p	O
=	O
0	O
.	O
014	O
,	O
HR	O
=	O
3	O
.	O
8	O
)	O
,	O
and	O
overall	O
survival	O
(	O
p	O
=	O
0	O
.	O
016	O
,	O
HR	O
=	O
3	O
.	O
2	O
)	O
in	O
the	O
subgroups	O
of	O
OSCC	O
patients	O
with	O
poor	O
differentiation	O
,	O
pN2	O
lymph	O
node	O
metastases	O
,	O
or	O
extracapsular	O
spread	O
(	O
n	O
=	O
150	O
)	O
.	O
LR	O
-	O
HPV	O
infections	O
may	O
have	O
an	O
important	O
role	O
in	O
determining	O
the	O
clinical	O
outcomes	O
of	O
certain	O
OSCC	O
patients	O
bearing	O
specific	O
risk	O
factors	O
.	O

%	O
%	O
METHODS	O

Study	O
population	O
and	O
design	O

This	O
study	O
was	O
designed	O
as	O
a	O
single	B-Study_Type
-	I-Study_Type
center	I-Study_Type
,	I-Study_Type
retrospective	I-Study_Type
case	I-Study_Type
series	I-Study_Type
aimed	O
at	O
investigating	O
the	O
molecular	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV	O
infections	O
among	O
Taiwanese	O
OSCC	O
patients	O
referred	O
to	O
the	O
Chang	O
Gung	O
Memorial	O
Hospital	O
,	O
Linkou	O
Medical	O
Center	O
,	O
Taoyuan	O
,	O
Taiwan	B-Study_Location
.	I-Study_Location

The	O
investigation	O
was	O
powered	O
to	O
detect	O
prevalence	B-Incidence_or_Prevalence
rates	O
as	O
low	O
as	O
0	O
%	O
in	O
a	O
reliable	O
manner	O
.	O

We	O
calculated	O
that	O
the	O
absence	O
of	O
HPV	O
infections	O
among	O
400	O
OSCC	O
patients	O
would	O
generate	O
a	O
one	O
-	O
sided	O
97	O
.	O
5	O
%	O
conﬁdence	O
interval	O
(	O
CI	O
)	O
between	O
0	O
%	O
and	O
0	O
.	O
92	O
%	O
.	O

Only	O
formalin	O
-	O
ﬁxed	O
,	O
parafﬁn	O
-	O
embedded	O
(	O
FFPE	O
)	O
specimens	B-HPV_Sample_Type
from	O
patients	B-Study_Cohort
with	I-Study_Cohort
newly	I-Study_Cohort
diagnosed	I-Study_Cohort
OSCC	I-Study_Cohort
were	O
included	O
in	O
this	O
study	O
.	O

All	O
of	O
the	O
OSCC	O
patients	O
were	O
treated	O
with	O
radical	O
surgery	O
with	O
curative	O
intent	O
.	O

Two	O
distinct	O
cohorts	O
were	O
enrolled	O
in	O
this	O
study	O
(	O
2005	B-Study_Cohort
cohort	I-Study_Cohort
,	I-Study_Cohort
n	I-Study_Cohort
=	I-Study_Cohort
204	I-Study_Cohort
;	O
2010	B-Study_Cohort
cohort	I-Study_Cohort
,	I-Study_Cohort
n	I-Study_Cohort
=	I-Study_Cohort
206	I-Study_Cohort
)	O
.	O

The	O
inclusion	O
criteria	O
were	O
as	O
follows	O
:	O
(	O
a	O
)	O
pathologically	O
proven	O
OSCC	O
,	O
(	O
b	O
)	O
presence	O
of	O
a	O
previously	O
untreated	O
tumor	O
scheduled	O
for	O
radical	O
surgery	O
with	O
or	O
without	O
neck	O
dissection	O
,	O
and	O
(	O
c	O
)	O
absence	O
of	O
suspected	O
distant	O
metastases	O
on	O
imaging	O
.	O

Patients	O
who	O
refused	O
to	O
participate	O
or	O
did	O
not	O
undergo	O
radical	O
surgery	O
were	O
excluded	O
.	O

The	O
traditional	O
risk	O
fac	O
-	O
tors	O
for	O
OSCC	O
were	O
extracted	O
from	O
clinical	O
records	O
and	O
classiﬁed	O
as	O
described	O
previously	O
.	O

The	O
following	O
variables	O
were	O
collected	O
:	O
sex	O
,	O
age	O
,	O
alcohol	O
drinking	O
,	O
betel	O
quid	O
chewing	O
,	O
cigarette	O
smok	O
-	O
ing	O
,	O
tumor	O
location	O
,	O
histological	O
differentiation	O
,	O
pathological	O
tumor	O
status	O
,	O
pathological	O
lymph	O
node	O
status	O
,	O
pathological	O
stage	O
,	O
extra	O
-	O
capsular	O
spread	O
,	O
and	O
treatment	O
modality	O
.	O

The	O
tumor	O
location	O
was	O
determined	O
by	O
direct	O
oral	O
inspection	O
and	O
conﬁrmed	O
by	O
pathologi	O
-	O
cal	O
examination	O
.	O

OSCC	O
patients	O
were	O
staged	O
according	O
to	O
the	O
2002	O
American	O
Joint	O
Committee	O
on	O
Cancer	O
6th	O
edition	O
staging	O
criteria	O
.	O

Postoperative	O
radiotherapy	O
or	O
concomitant	O
chemoradiation	O
ther	O
-	O
apy	O
were	O
used	O
for	O
adjuvant	O
treatment	O
of	O
patients	O
with	O
advanced	O
OSCC	O
.	O

The	O
classiﬁcation	O
of	O
therapeutic	O
outcomes	O
has	O
been	O
previ	O
-	O
ously	O
described	O
.	O

The	O
Institutional	O
Review	O
Board	O
approved	O
the	O
study	O
protocol	O
,	O
and	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
participants	O
.	O

DNA	O
extraction	O
and	O
MY11	O
/	O
GP6	O
+	O
polymerase	B-HPV_Lab_Technique
chain	I-HPV_Lab_Technique
reaction	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
)	O

Primary	O
tumors	O
were	O
excised	B-HPV_Sample_Collection_Method
with	O
safety	O
margins	O
larger	O
than	O
1	O
cm	O
(	O
all	O
peripheral	O
and	O
deep	O
margins	O
)	O
.	O

The	O
FFPE	O
tumor	O
tissues	B-HPV_Sample_Type
were	O
prepared	O
for	O
DNA	O
extraction	O
as	O
previously	O
described	O
.	O
µL	O
of	O
the	O
50	O
µL	O
eluted	O
DNA	O
solution	O
was	O
used	O
as	O
the	O
PCR	B-HPV_Lab_Technique
template	O
.	O

An	O
HPV	O
L1	O
gene	O
PCR	B-HPV_Lab_Technique
assay	O
was	O
used	O
to	O
screen	O
for	O
HPV	O
infections	O
.	O

HPV	O
DNA	O
was	O
ampliﬁed	O
using	O
MY11	O
/	O
biotinylated	O
GP6	O
+	O
primers	O
target	O
-	O
ing	O
the	O
L1	O
region	O
,	O
which	O
produced	O
a	O
192	O
-	O
bp	O
DNA	O
fragment	O
.	O

DNA	O
quality	O
was	O
assessed	O
in	O
each	O
run	O
using	O
a	O
�	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
globin	I-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
.	I-HPV_Lab_Technique

All	O
of	O
the	O
obtained	O
specimens	B-HPV_Sample_Type
were	O
found	O
to	O
be	O
�	O
-	O
globin	O
-	O
positive	O
.	O

HPV	O
genotyping	O
by	O
Eastchip®	O
HPV	O
blot	O

Specimens	B-HPV_Sample_Type
were	O
further	O
tested	O
for	O
the	O
presence	O
of	O
HPV	O
and	O
its	O
genotypes	O
by	O
amplifying	O
50	O
µL	O
of	O
the	O
DNA	O
extracts	O
using	O
the	O
EasyChip®	O
HPV	O
Blot	O
genotyping	O
assay	O
(	O
King	O
Car	O
Ltd	O
,	O
Ilan	O
,	O
Taiwan	O
)	O
.	O

HPV	O
type	O
-	O
speciﬁc	O
oligonucleotide	O
probes	O
were	O
immobilized	O
on	O
a	O
nylon	O
membrane	O
for	O
reverse	O
-	O
blot	O
hybridization	O
to	O
detect	O
HPV	O
DNA	O
in	O
a	O
single	O
assay	O
.	O
Two	O
independent	O
PCR	B-HPV_Lab_Technique
products	O
of	O
each	O
sam	O
-	O
ple	O
were	O
hybridized	O
with	O
an	O
HPV	O
blot	O
,	O
and	O
the	O
two	O
HPV	O
blot	O
results	O
were	O
compared	O
with	O
each	O
other	O
.	O

The	O
HPV	O
blot	O
kit	O
enabled	O
the	O
dif	O
-	O
ferential	O
detection	O
of	O
39	O
HPV	O
types	O
(	O
i	O
.	O
e	O
.	O

,	O
HPV	O
types	O
6	O
,	O
11	O
,	O
16	O
,	O
18	O
,	O
26	O
,	O
31–33	O
,	O
35	O
,	O
37	O
,	O
39	O
,	O
42–45	O
,	O
51–56	O
,	O
58	O
,	O
59	O
,	O
61	O
,	O
62	O
,	O
66–70	O
,	O
71	O
[	O
CP8061	O
]	O
,	O

72	O
,	O
74	O
,	O
81	O
[	O
CP8304	O
]	O
,	O
82	O
[	O
MM4	O
]	O
,	O
83	O
[	O
MM7	O
]	O
,	O
84	O
[	O
MM8	O
]	O
,	O
and	O
L1AE5	O
)	O
.	O

The	O
high	O
-	O
risk	O
HPV	O
types	O
included	O
types	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
56	O
,	O
58	O
,	O
59	O
,	O
and	O
68	O
,	O
whereas	O
HPV	O
types	O
6	O
,	O
11	O
,	O
26	O
,	O
32	O
,	O
37	O
,	O
42–44	O
,	O

53–55	O
,	O
61	O
,	O
62	O
,	O
66	O
,	O
67	O
,	O
69–72	O
,	O
74	O
,	O
81–84	O
,	O
and	O
L1AE5	O
were	O
classi	O
-	O

ﬁed	O
as	O
low	O
-	O
risk	O
types	O
.	O

HR	O
-	O
HPV	O
positivity	O
was	O
deﬁned	O
as	O
having	O
at	O
least	O
one	O
of	O
the	O
13	O
high	O
-	O
risk	O
types	O
.	O

Patients	O
with	O
both	O
high	O
-	O
risk	O
and	O
low	O
-	O
risk	O
HPV	O
types	O
were	O
classiﬁed	O
as	O
having	O
HR	O
-	O
HPV	O
infec	O
-	O
tions	O
.	O

LR	O
-	O
HPV	O
positivity	O
was	O
deﬁned	O
by	O
the	O
presence	O
of	O
single	O
or	O
multiple	O
infections	O
by	O
low	O
-	O
risk	O
HPV	O
genotypes	O
only	O
.	O

Statistical	O
analysis	O

The	O
overall	O
prevalence	B-Incidence_or_Prevalence
of	O
the	O
HPV	O
genotypes	O
was	O
calculated	O
,	O
and	O
the	O
distribution	O
of	O
speciﬁc	O
HPV	O
genotypes	O
was	O
expressed	O
as	O
the	O
proportion	O
of	O
HPV	O
DNA	O
-	O
positive	O
specimens	B-HPV_Sample_Type
among	O
all	O
of	O
the	O

Table	O
1	O

Molecular	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV	O
infections	O
in	O
patients	O
with	O
oral	O
cavity	O
squamous	O
cell	O
carcinoma	O
stratiﬁed	O
by	O
calendar	O
year	O
.	O

Abbreviations	O
:	O
HPV	O
,	O
human	O
papillomavirus	O
.	O

a	O
P	O
values	O
were	O
calculated	O
using	O
the	O
Fisher’s	O
exact	O
test	O
(	O
patients	O
positive	O
for	O
spe	O
-	O
ciﬁc	O
HPV	O
genotypes	O
versus	O
HPV	O
-	O
negative	O
subjects	O
)	O
according	O
to	O
the	O
calendar	O
year	O
.	O

OSCC	O
cases	O
.	O

Descriptive	O
statistics	O
were	O
summarized	O
using	O
frequen	O
-	O
cies	O
,	O
percentages	O
,	O
means	O
,	O
medians	O
,	O
ranges	O
,	O
and	O
standard	O
deviations	O
(	O
SDs	O
)	O
.	O

Categorical	O
variables	O
were	O
analyzed	O
using	O
the	O
chi	O
-	O
square	O
test	O
or	O
the	O
Fisher’s	O
exact	O
test	O
,	O
as	O
appropriate	O
.	O

Follow	O
-	O
up	O
visits	O
continued	O
until	O
December	O
2012	O
.	O

The	O
2	O
-	O
year	O
local	O
control	O
,	O
neck	O
control	O
,	O
dis	O
-	O
tant	O
metastasis	O
,	O
DFS	O
,	O
DSS	O
,	O
and	O
OS	O
rates	O
were	O
calculated	O
using	O
the	O
Kaplan–Meier	O
method	O
(	O
log	O
-	O
rank	O
test	O
)	O
.	O

Multivariate	O
Cox	O
regression	O
analysis	O
with	O
a	O
backward	O
selection	O
procedure	O
was	O
used	O
to	O
identify	O
the	O
independent	O
prognostic	O
factors	O
.	O

The	O
results	O
were	O
expressed	O
as	O
hazard	O
ratios	O
(	O
HR	O
)	O
and	O
95	O
%	O
CI	O
.	O

We	O
calculated	O
the	O
study	O
power	O
for	O
the	O
survival	O
analysis	O
using	O
the	O
R	O
software	O
(	O
Version	O
2	O
.	O
15	O
.	O

3	O
;	O
R	O
Foundation	O
for	O
Statistical	O
Computing	O
,	O
)	O
.	O

Other	O
calcu	O
-	O
lations	O
were	O
performed	O
using	O
the	O
SPSS	O
software	O
(	O
version	O
17	O
.	O
0	O
;	O
SPSS	O
,	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Two	O
-	O
tailed	O
p	O
values	O
<	O
0	O
.	O
05	O
were	O
considered	O
statistically	O
signiﬁcant	O
.	O

